nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement
|
Nesteryuk, Vasyl |
|
|
|
8 |
p. e550-e555 |
artikel |
2 |
A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases
|
Itchins, Malinda |
|
|
|
8 |
p. 702-708 |
artikel |
3 |
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)
|
Kim, Kyung Hwan |
|
|
|
8 |
p. e536-e539 |
artikel |
4 |
An Effective Malignancy Prediction Model for Incidentally Detected Pulmonary Subsolid Nodules Based on Current and Prior CT Scans
|
Li, Shaolei |
|
|
|
8 |
p. e301-e310 |
artikel |
5 |
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
|
Zhou, Li |
|
|
|
8 |
p. 709-719 |
artikel |
6 |
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
|
Ahn, Myung-Ju |
|
|
|
8 |
p. 670-685 |
artikel |
7 |
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
|
Shah, Mohsin |
|
|
|
8 |
p. 731-736 |
artikel |
8 |
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)
|
Guisier, Florian |
|
|
|
8 |
p. e545-e549 |
artikel |
9 |
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer
|
Yu, Nathan Y. |
|
|
|
8 |
p. e526-e535 |
artikel |
10 |
CCND1 Messenger RNA Expression Is Correlated with EGFR Mutation Status in Lung Cancer
|
Sasaki, Hidefumi |
|
2007 |
|
8 |
p. 493-496 4 p. |
artikel |
11 |
Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report
|
Owen, Timothy |
|
|
|
8 |
p. e563-e567 |
artikel |
12 |
Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
|
Banks, Kian C. |
|
|
|
8 |
p. 694-701 |
artikel |
13 |
CyberKnife® Radiosurgery for Stage I Lung Cancer: Results at 36 Months
|
Brown, William T. |
|
2007 |
|
8 |
p. 488-492 5 p. |
artikel |
14 |
Developing a Prediction Model for Radiation Pneumonitis in Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy Combined With Clinical, Dosimetric Factors, and Laboratory Biomarkers
|
Huang, Bao-Tian |
|
|
|
8 |
p. e323-e331.e2 |
artikel |
15 |
Editorial Board
|
|
|
|
|
8 |
p. A1 |
artikel |
16 |
Editorial Board
|
|
|
|
|
8 |
p. A2 |
artikel |
17 |
Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the “PACIFIC” Era
|
Adachi, Hiroyuki |
|
|
|
8 |
p. 733-742 |
artikel |
18 |
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
|
Ahn, Myung J. |
|
|
|
8 |
p. 720-730 |
artikel |
19 |
Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell Lung Cancer: A Retrospective Study
|
Shi, Zheng |
|
|
|
8 |
p. 717-725.e1 |
artikel |
20 |
2007 Highlights from: the 43rd Annual Meeting of the American Society of Clinical Oncology Chicago, IL; June 2007
|
Ranganathan, Aarati |
|
2007 |
|
8 |
p. 468-475 8 p. |
artikel |
21 |
Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events
|
Guo, Mengni |
|
|
|
8 |
p. 686-693 |
artikel |
22 |
Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options
|
Leal, Jose Luis |
|
|
|
8 |
p. 643-658 |
artikel |
23 |
Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer
|
Petranovic, Milena |
|
|
|
8 |
p. 682-688.e5 |
artikel |
24 |
Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis
|
Kuang, Yuting |
|
|
|
8 |
p. 659-669 |
artikel |
25 |
Intraoperative Versus Preoperative Diagnosis of Lung Cancer: Differences in Treatments and Patient Outcomes
|
Mack, Shale J. |
|
|
|
8 |
p. 726-732 |
artikel |
26 |
Machine-Learning-Aided Prediction of Brain Metastases Development in Non–Small-Cell Lung Cancers
|
Visonà, Giovanni |
|
|
|
8 |
p. e311-e322 |
artikel |
27 |
Malignant Primary Pulmonary Tumor with Hemangiopericytoma-Like Features: Conventional Hemangiopericytoma Versus Solitary Fibrous Tumor
|
Radulescu, Dan |
|
2007 |
|
8 |
p. 504-508 5 p. |
artikel |
28 |
Outcome of Incidental Pulmonary Nodules in a Real-World Setting
|
Vindum, Helene Hjorth |
|
|
|
8 |
p. 673-681 |
artikel |
29 |
Outcomes of Intraocular Metastasis From Lung Cancer in the Era of Targeted Therapy: A Systematic Review and Pooled Analysis
|
Maller, Bradley |
|
|
|
8 |
p. e519-e525 |
artikel |
30 |
Paclitaxel/Carboplatin/Gemcitabine Versus Gemcitabine/Vinorelbine in Advanced Non–Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network
|
Greco, F. Anthony |
|
2007 |
|
8 |
p. 483-487 5 p. |
artikel |
31 |
Patient Demographics in HOG LUN 01-24 Versus SWOG 9504: Apples Versus Oranges?
|
Gaspar, Laurie E. |
|
2007 |
|
8 |
p. 466-467 2 p. |
artikel |
32 |
PET-CT SUVmax and Endobronchial Ultrasound Features for Prediction of Malignancy: A Prospective Study
|
Faria, Nuno |
|
|
|
8 |
p. 753-760 |
artikel |
33 |
Phase II Pharmacogenomics-Based Adjuvant Therapy Trial in Patients with Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial 0720
|
Bepler, Gerold |
|
2007 |
|
8 |
p. 509-511 3 p. |
artikel |
34 |
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report
|
Wang, Pascal |
|
|
|
8 |
p. e568-e572 |
artikel |
35 |
Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis
|
Alnimer, Yanal |
|
|
|
8 |
p. e510-e518 |
artikel |
36 |
Prognostication Using the Japanese Risk Calculator for Lung Cancer Surgery
|
Ozawa, Hiroki |
|
|
|
8 |
p. 743-752.e2 |
artikel |
37 |
Prognostic Factors in Stage III Non–Small-Cell Lung Cancer
|
Ademuyiwa, Foluso O. |
|
2007 |
|
8 |
p. 478-482 5 p. |
artikel |
38 |
Prognostic Impact of the Immune-Cell Infiltrate in N1-Positive Non–Small-Cell Lung Cancer
|
Eichhorn, Florian |
|
|
|
8 |
p. 706-716.e1 |
artikel |
39 |
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer
|
Desai, Aakash |
|
|
|
8 |
p. 689-695.e1 |
artikel |
40 |
Relief from Sleep Apnea After Radiation and Chemotherapy
|
Ursavaş, Ahmet |
|
2007 |
|
8 |
p. 502-503 2 p. |
artikel |
41 |
Safety of Irinotecan/Cisplatin Versus Etoposide/Cisplatin for Patients with Extensive-Stage Small-Cell Lung Cancer: A Metaanalysis
|
Jiang, Lei |
|
2007 |
|
8 |
p. 497-501 5 p. |
artikel |
42 |
Table of Contents
|
|
|
|
|
8 |
p. A3-A6 |
artikel |
43 |
Table of Contents
|
|
|
|
|
8 |
p. A3-A5 |
artikel |
44 |
Targeted therapy for lung cancer with paraneoplastic disseminated intravascular coagulation: A case report and pooled analysis
|
Pevner, Justin L. |
|
|
|
8 |
p. e540-e544 |
artikel |
45 |
The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX)
|
Bang, Tami J. |
|
|
|
8 |
p. e501-e509 |
artikel |
46 |
The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-Immunotherapy Era: A Single Institution Series
|
Gross, Andrew J. |
|
|
|
8 |
p. 696-705 |
artikel |
47 |
U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome
|
Kaland, David A. |
|
|
|
8 |
p. e556-e562 |
artikel |